Compounds > n-leucyldoxorubicin
Page last updated: 2024-12-06

n-leucyldoxorubicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-leucyldoxorubicin: structure given in first source; a prodrug of doxorubicin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68897
CHEMBL ID3989596
SCHEMBL ID1231191
MeSH IDM0198519

Synonyms (32)

Synonym
rp-39937
ct-012002
leu-dox
e-88/032
doxogenix l
leurubicin
l-adr
(2s)-2-amino-n-[(2s,3s,4s,6r)-3-hydroxy-2-methyl-6-[[(1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]oxan-4-yl]-4-methylpentanamide
70774-25-3
n-leucyldoxorubicin
n-l-leucyldoxorubicin
n-leucyl-doxorubicin
n-l-leucyl-doxorubicin
leucyl-doxorubicin
leurubicina
leurubicine
unii-1z20mgk851
leurubicin [inn]
1z20mgk851 ,
leurubicinum
(8s,10s)-10-((3-((s)-2-amino-4-methylvaleramido)-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
leurubicina [inn-spanish]
leurubicinum [inn-latin]
leurubicine [inn-french]
(8s,10s)-10-((3-((s)-2-amino-4-methylvaleramido)-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
SCHEMBL1231191
CHEMBL3989596
3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-[(2-amino-1-hydroxy-4-methylpentylidene)amino]-2,3,6-trideoxyhexopyranoside
DTXSID50991030
(s)-2-amino-n-((2s,3s,4s,6r)-3-hydroxy-2-methyl-6-(((1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl)oxy)tetrahydro-2h-pyran-4-yl)-4-methylpentanamide
Q27253246
AKOS040747057

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A pharmacokinetic study of N-L-leucyl-doxorubicin, a new derivative of doxorubicin, has been undertaken during a phase I trial in 19 patients with advanced cancer after intravenous bolus administration at doses ranging from 30 to 240 mg/m2."( Human pharmacokinetics of N-L-leucyl-doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities.
Baurain, R; Bugat, R; Canal, P; de Forni, M; Magis, A; Marty, M; Pujade-Lauraine, E; Ramon, M; Robert, J; Tresca, P, 1992)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1447933Retention time of compound by LC-MS analysis2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs.
AID1447948Cytotoxicity against human U87MG cells treated with MJ02 assessed as reduction in cell survival after 96 hrs by MTT assay2017Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10
Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (71.43)18.2507
2000's2 (14.29)29.6817
2010's2 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.53 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoleucine
Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.		1.9810aspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
vintriptol
[no description available]		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Glial Cell Tumors
[description not available]		02.1510
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.1510
Sarcoma, Epithelioid
[description not available]		02.0410
Cancer of the Uterus
[description not available]		02.0410
Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.		02.0410
Uterine Neoplasms
Tumors or cancer of the UTERUS.		02.0410
Breast Cancer
[description not available]		02.6830
Leucocythaemia
[description not available]		01.9810
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.6830
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9810
Carcinoma, Oat Cell
[description not available]		01.9910
Carcinoma, Non-Small Cell Lung
[description not available]		01.9910
Cancer of Lung
[description not available]		01.9910
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		01.9910
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9910
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		01.9910
Malignant Melanoma
[description not available]		0210
Cancer of Skin
[description not available]		0210
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		0210
Skin Neoplasms
Tumors or cancer of the SKIN.		0210
Benign Neoplasms
[description not available]		03.7721
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.7721
Cancer of Ovary
[description not available]		01.9810
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		01.9810
Mucositis, Oral
[description not available]		03.3611
Stomatitis
INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.		03.3611
Cardiac Diseases
[description not available]		01.9710
Leukocytopenia
[description not available]		01.9710
Heart Diseases
Pathological conditions involving the HEART including its structural and functional abnormalities.		01.9710
Leukopenia
A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).		01.9710